Company Profile
Intellia Stock Price, News & Analysis
- Ticker:
- NTLA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
10.67 USD (-0.56%)
Close
Last updated: July 27, 2026
1.83B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, NTLA closed down 0.56% at $10.67. No new same-company headline was identified in the current news window.
Company overview
Business overview
Intellia Therapeutics is a gene-editing company building in vivo and ex vivo CRISPR programs across serious genetic diseases.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Intellia sits in advanced gene-editing biotechnology.
Business Model Characteristics
The company relies on clinical data, collaboration economics, and platform validation for its next wave of value creation.
Position Within the Biotechnology Landscape
Intellia is one of the leading in vivo editing names, and the stock remains highly sensitive to platform and safety readouts.
Future catalysts
What matters most for Intellia from here is MAGNITUDE-2 and ATTR-CM. That matters because the company is now talking about Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE. That is the piece most likely to shape sentiment in the near term.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
- 03
- 04
- 05
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
KRYS · Source: Krystal Biotech
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Intellia (NTLA)?
Intellia (NTLA) most recently closed at 10.67 USD, a -0.56% move versus the previous session.
What is the market cap of Intellia (NTLA)?
Intellia currently has a market capitalization of 1.83B USD on BioPharmSignal.
What does Intellia do?
Intellia Therapeutics is a gene-editing company building in vivo and ex vivo CRISPR programs across serious genetic diseases.
On which exchange is NTLA stock listed?
Intellia (NTLA) is associated with NASDAQ, United States, Biopharma.
What is MAGNITUDE-2?
What matters most for Intellia from here is MAGNITUDE-2 and ATTR-CM.
Which conditions is Intellia targeting with MAGNITUDE-2?
Intellia is associated with genetic disease based on its company overview and current catalyst commentary.
How does Intellia describe recent progress with MAGNITUDE-2?
What matters most for Intellia from here is MAGNITUDE-2 and ATTR-CM.
What is ATTR-CM?
What matters most for Intellia from here is MAGNITUDE-2 and ATTR-CM.